Skip to main content

Modernization of Tissue-based, Biomarker-led Clinical Research

Dr Stephanie G. Craig
Dr Stephanie G. Craig Lecturer in Precision Medicine at the Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast

Automated staining platforms and digital slide scanners have revolutionized tissue-based biomarker research by providing a powerful platform in which to conduct reproducible, quantitative biomarker-led studies at scale.

Use of machine learning and artificial intelligence approaches to analyze these biomarkers enables sensitive, specific, and rapid biomarker assessment in situ. In this talk, we will be reviewing the implementation and technical challenges faced in modern tissue-based, biomarker-led research from wet-lab validation to digital assessment. To do so we will review published work from our lab that has utilized automated staining and slide digitization as an aid to clinical research (for research use only. Not for use in diagnostic procedures) in immunohistochemistry, RNA in situ hybridization, multiplex immunofluorescence, and artificial intelligence studies.

학습 목표

  • Learn how automated staining and slide digitization can reduce staining variability and aid in quantitative biomarker assessment at scale
  • Understand how digitization of molecular pathology assessment lends itself to multi- and cross-disciplinary research investigations

For Research Use Only. Not for use in diagnostic procedures.


발표자 소개

Dr Stephanie G. Craig
Dr Stephanie G. Craig , Lecturer in Precision Medicine at the Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast

Stephanie is a Lecturer in Precision Medicine at the Patrick G. Johnson Centre for Cancer Research, Queen’s University Belfast. She has a breath of experience in the application and validation of translational cancer research methodologies using molecular pathology techniques (immunohistochemistry, in situ hybridisation, multiplex immunofluorescence) and statistics. Her research focuses on predictive biomarker studies and understanding confounding variables that influence the prediction of poor prognosis subgroups in cancer research including reproducible study design, choice of molecular test and assessment criteria.

Related Content

Leica Biosystems 콘텐츠는 Leica Biosystems 웹사이트 이용 약관의 적용을 받으며, 이용 약관은 다음에서 확인할 수 있습니다. 법적고지. 라이카 바이오시스템즈 웨비나, 교육 프레젠테이션 및 관련 자료는 특별 주제 관련 일반 정보를 제공하지만 의료, 규정 또는 법률 상담으로 제공되지 않으며 해석되어서는 안 됩니다. 관점과 의견은 발표자/저자의 개인 관점과 의견이며 라이카 바이오시스템즈, 그 직원 또는 대행사의 관점이나 의견을 나타내거나 반영하지 않습니다. 제3자 자원 또는 콘텐츠에 대한 액세스를 제공하는 콘텐츠에 포함된 모든 링크는 오직 편의를 위해 제공됩니다.

모든 제품 사용에 다양한 제품 및 장치의 제품 정보 가이드, 부속 문서 및 작동 설명서를 참조해야 합니다.

Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.